Is 4161.TWO overvalued or undervalued?

4161.TWO currently has a P/E ratio of 11.51. Relative to the sector average of 26.70, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Bioptik Technology Incorporation stock?

Bioptik Technology Incorporation trades on TWO. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 4161.TWO?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 4161.TWO protect my money against local inflation?

Many investors in Latin America buy international stocks like 4161.TWO to protect their purchasing power. Because 4161.TWO is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 4161.TWO shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 4161.TWO a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 4161.TWO diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks4161.TWO

Bioptik Technology Incorporation

NT$21.40-NT$0.10-0.47%

TWO / TWD

Market cap

NT$1.3B

P/E

11.5

EPS (TTM)

NT$0.06

Dividend yield

3.27%

Beta

0.25

1Y return

-21.47%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$27M2021

$25M2022

$27M2023

$26M2024

$27M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.47Low
Current ratio1.87
Cash ratio0.78
Net margin11.8%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

4161.TWO11.5
Healthcare sector median26.7
S&P 50022.0

Trades about 57% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.25
Price to book1.24
EPS (TTM)NT$0.06
Payout ratio1,469%
FCF yield1.74%

Range & risk

NT$21.20NT$28.00

Trading in the lower third of its 52-week band

Beta0.25

Profile

What Bioptik Technology Incorporation actually does

Bioptik Technology Incorporation operates as a global entity, focusing on the creation and distribution of medical instruments and diagnostic chemicals. The company's product line encompasses the EasyMate series of blood glucose monitoring systems, as well as comprehensive diagnostic devices designed to measure blood glucose, cholesterol, and uric acid levels, complete with their essential test strips. Beyond its healthcare offerings, Bioptik also provides a range of skincare solutions, including those formulated with hyaluronic acid, alongside various dietary supplements. Uniquely, the company diversifies its business by supplying biodiesel products. Founded in 1999, Bioptik Technology Incorporation is headquartered in Zhunan, Taiwan.

CEO

Yao-Jen Tu

Employees

Headquarters

Zhunan

Founded

2012-06-20

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 4161.TWO and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

4161.TWO has a beta of 0.25, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Bioptik Technology Incorporation